By Tony Fong

Agilent Technologies today reported a 9 percent slide in its Bio-Analytical Measurement segment amid a 21 percent drop in overall revenues for its fiscal fourth quarter, to close out "an extraordinarily difficult year," according to the firm's president and chief executive.

The company also said that its planned $1.5 billion acquisition of Varian is now expected to close in early 2010 instead of the end of 2009 as previously planned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.